BioSpace News Archive

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that pending the receipt of additional information from the Company, Nasdaq has halted the trading in the Company’s common stock

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a poster presentation as part of the 2020 American Academy of Neurology Science Highlights virtual platform. The presentation will include baseline demographics as well as preliminary pharmacokinetic and biomarker data from the TOPAZ

Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acquired pneumonia (CAP) guidelines

Since the outbreak of COVID-19, researchers at the Wuhan Institute of Virology of the Chinese Academy of Science have been working on the frontline, undertaking a range of R&D tasks to prevent and control the pandemic.

Centene Corporation (NYSE: CNC) today issued a press release announcing that it will host an investor meeting, in a virtual format, on Friday, June 12, 2020 . Michael F. Neidorff , Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke , Executive Vice President and Chief Financial Officer, of Centene Corporation will h

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that pending the receipt of additional information from the Company, Nasdaq has halted the trading in the Company’s common stock.

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $250,000,000 of shares of its common stock.

Teclistamab Data Featured as an Oral Presentation during ASCO Virtual Scientific Program

Amivantamab-treated patients achieved durable remissions in CHRYSALIS study; data will be presented during ASCO Virtual Scientific Program [18-May-2020] RARITAN, N.J. , May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 1 CHRYSALIS study ( NCT02609776 ) evaluating amivantamab (JNJ-6372) in

Data from SER-109 Phase 3 study in recurrent C. difficile infection expected mid-2020